NCT06067841View on ClinicalTrials.gov

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

August 24, 2029

Study Completion Date

July 27, 2031

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

BMS-986460

Specified dose on specified days.

Trial Locations (7)

10065

Local Institution - 0002, New York

27710

Local Institution - 0001, Durham

34232

Local Institution - 0007, Sarasota

78229

Local Institution - 0008, San Antonio

94304

Local Institution - 0004, Palo Alto

98109

Local Institution - 0005, Seattle

02215

Local Institution - 0003, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06067841 - A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter